XNYS · Medical Distribution
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$276.79+0.91%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
—
Not scored in the latest run — the model needs every factor family, and one was unavailable for this name.
Score components
TickerWhale View
No narrated read for this name yet — the deterministic factors still carry the analysis.
What helps
- Technical
- Valuation
- Sentiment Signal
What to watch
- Quality & growth
Quality & growth
30%40Weak
- Revenue growth 14.2%
- EPS growth 12.1%
Valuation
25%52Moderate
- P/E 38.1
- EV/Sales 0.3
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
#207 by market cap in our coverage · ~57,700 employees · Listed 1983-08-04 · www.cardinalhealth.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
Revenue growth (sector)Top 36%
Gross margin (sector)Top 98%
P/E (sector)Pricier than 61%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
90/100Strong
Weighted composite of momentum, trend, relative strength, oscillators, volatility, drawdown and liquidity — not yet ranked against the universe in this run · 25% of the TickerWhale Score
Classic chart indicators
Strong Buy
6 buy · 1 sell · 1 neutral of 8 votes
TickerWhale reads CAH's technical setup as strong at 90/100, not yet ranked against the universe in this run. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+23.5%
- vs 50-day+14.3%
Momentum
Constructive
- RSI (14)77 · sell
- Stochasticbuy
- CCIbuy
- Williams %Rneutral
Trend
Constructive
- ADX (14) trend strength31· trending
- MACD (12,26,9)buy(histogram 2.128)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 5 buy · 1 sell · 1 neutral.
Result — 6 buy vs 1 sell of 8 votes = Strong Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)38.1
- P/S (TTM)0.3
- P/B—
- EV/EBITDA—
- EV/Sales0.3
- PEG3.15
Profitability & returns
- Gross margin3.8%
- Net margin0.7%
- ROE—
- Debt/Equity—
Growth
- Revenue growth (YoY)14.2%
- EPS growth (YoY)12.1%
Green favourable · red stretched — multiples and D/E vs sector peers, margins and growth vs absolute thresholds.
Market capitalisation — $65.3B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Jun '26 | Jun '25 | Jun '24 |
|---|---|---|---|
| Revenue | $254.2B | $222.6B | $226.8B |
| Gross profit | $9.8B | $8.2B | $7.4B |
| Operating income | $2.6B | $2.3B | $1.3B |
| Net income | $1.7B | $1.6B | $852M |
| EPS (diluted) | $7.23 | $6.45 | $3.45 |
| Free cash flow | $4.6B | $1.9B | $3.3B |
| Cash | $4.9B | $3.9B | $5.1B |
| Total debt | $8.9B | $8.5B | $5.1B |
| Equity | -$2.9B | -$2.8B | -$3.2B |
| Net debt | $4.0B | $4.7B | -$41M |
| Debt / equity | -3.08 | -3.07 | -1.58 |
| Liabilities / assets | 1.05 | 1.05 | 1.07 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CAHCurrentCardinal Health | — | 90 | 38.1 | — | — | 0.3 | $276.79 | +0.91% | +14.2% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.